TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Average PT from Brokerages

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has been assigned an average rating of "Buy" from the six research firms that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $8.50.

Several research firms recently issued reports on TCRX. Morgan Stanley reissued an "overweight" rating and set a $10.00 price target on shares of TScan Therapeutics in a research report on Friday, March 14th. Wedbush restated an "outperform" rating and issued a $7.00 price target on shares of TScan Therapeutics in a research report on Tuesday. Needham & Company LLC reiterated a "buy" rating and issued a $9.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, April 8th. Barclays cut their price target on TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a research note on Friday, March 7th. Finally, HC Wainwright cut their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday.

TScan Therapeutics Trading Up 0.2 %

Shares of TCRX traded up $0.00 on Friday, hitting $1.36. 22,733 shares of the stock traded hands, compared to its average volume of 359,808. The firm has a market capitalization of $77.08 million, a P/E ratio of -1.29 and a beta of 1.06. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics has a 1 year low of $1.02 and a 1 year high of $9.69. The stock's 50 day moving average is $1.52 and its two-hundred day moving average is $2.78.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02. The business had revenue of $2.17 million for the quarter, compared to analysts' expectations of $1.62 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. As a group, sell-side analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Trading of TScan Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new position in TScan Therapeutics during the 4th quarter worth approximately $32,000. Prudential Financial Inc. acquired a new position in shares of TScan Therapeutics during the 4th quarter worth approximately $32,000. ProShare Advisors LLC bought a new position in shares of TScan Therapeutics in the 4th quarter valued at about $40,000. Squarepoint Ops LLC acquired a new stake in TScan Therapeutics in the 4th quarter valued at about $59,000. Finally, Wells Fargo & Company MN increased its position in TScan Therapeutics by 41.1% during the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after buying an additional 5,694 shares during the last quarter. Institutional investors and hedge funds own 82.83% of the company's stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.